Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients

NCT01729663 is registered in ClinicalTrials.gov with Laboratorio Pablo Cassara S.R.L. as lead sponsor.

NCT NCT01729663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01729663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients
Lead sponsor
Laboratorio Pablo Cassara S.R.L.
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 30, 2009
Completion date
Not reported
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma